156 related articles for article (PubMed ID: 6161630)
1. Tumour-marker levels and prognosis in malignant teratoma of the testis.
Germa-Lluch JR; Begent RH; Bagshawe KD
Br J Cancer; 1980 Dec; 42(6):850-5. PubMed ID: 6161630
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of early serum tumor marker half-life in metastatic testicular teratoma.
Stevens MJ; Norman AR; Dearnaley DP; Horwich A
J Clin Oncol; 1995 Jan; 13(1):87-92. PubMed ID: 7528272
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors in clinical stage I non-seminomatous germ-cell tumours of the testis.
Raghavan D; Peckham MJ; Heyderman E; Tobias JS; Austin DE
Br J Cancer; 1982 Feb; 45(2):167-73. PubMed ID: 6174137
[TBL] [Abstract][Full Text] [Related]
4. Non-seminoma germ cell tumours (malignant teratoma) of the testis. Results of treatment and an analysis of prognostic factors.
Peckham MJ; Barrett A; McElwain TJ; Hendry WF; Raghavan D
Br J Urol; 1981 Apr; 53(2):162-72. PubMed ID: 6165424
[TBL] [Abstract][Full Text] [Related]
5. Further advances in the management of malignant teratomas of the testis and other sites.
Newlands ES; Begent RH; Rustin GJ; Parker D; Bagshawe KD
Lancet; 1983 Apr; 1(8331):948-51. PubMed ID: 6188011
[TBL] [Abstract][Full Text] [Related]
6. Serum tumour marker regression rate following chemotherapy for malignant teratoma.
Horwich A; Peckham MJ
Eur J Cancer Clin Oncol; 1984 Dec; 20(12):1463-70. PubMed ID: 6209145
[TBL] [Abstract][Full Text] [Related]
7. [Biological markers for tumours of the testis. Their use in diagnosis, prognosis and follow-up in 200 cases (author's transl)].
Bellet D; Caillaud JM; Droz JP; Delarue JC; Bohuon C
Nouv Presse Med; 1981 Nov; 10(40):3293-7. PubMed ID: 6170931
[TBL] [Abstract][Full Text] [Related]
8. Applications of biologic tumor markers in testicular cancer.
Javadpour N
Cancer Treat Rep; 1979; 63(9-10):1643-7. PubMed ID: 91433
[TBL] [Abstract][Full Text] [Related]
9. Serum alpha-fetoprotein and human chorionic gonadotropin in the management of testicular tumors.
Lange PH
Natl Cancer Inst Monogr; 1978 Dec; (49):215-7. PubMed ID: 86163
[TBL] [Abstract][Full Text] [Related]
10. Prognosis following chemotherapy for metastatic malignant teratoma.
Horwich A; Easton D; Husband J; Nicholas D; Peckham MJ
Br J Urol; 1987 Jun; 59(6):578-83. PubMed ID: 2446691
[TBL] [Abstract][Full Text] [Related]
11. [Diagnostic progress in testicular carcinoma].
Aiginger P; Kolbe H; Kühböck J; Spona J
Acta Med Austriaca; 1978; 5(4-5):159-61. PubMed ID: 91300
[TBL] [Abstract][Full Text] [Related]
12. Brain metastases in malignant teratoma: a review of four years' experience and an assessment of the role of tumour markers.
Kaye SB; Bagshawe KD; McElwain TJ; Peckham MJ
Br J Cancer; 1979 Mar; 39(3):217-23. PubMed ID: 88952
[TBL] [Abstract][Full Text] [Related]
13. Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancer.
de Wit R; Sylvester R; Tsitsa C; de Mulder PH; Sleyfer DT; ten Bokkel Huinink WW; Kaye SB; van Oosterom AT; Boven E; Vermeylen K; Stoter G
Br J Cancer; 1997; 75(3):432-5. PubMed ID: 9020492
[TBL] [Abstract][Full Text] [Related]
14. The value of AFP and HCG half lives in predicting the efficacy of combination chemotherapy in patients with non-seminomatous germ cell tumors of the testis.
Willemse PH; Sleijfer DT; Schraffordt Koops H; De Bruijn HW; Oosterhuis JW; Brouwers TM; Ockhuizen T; Marrink J
Oncodev Biol Med; 1981; 2(1-2):129-34. PubMed ID: 6170953
[TBL] [Abstract][Full Text] [Related]
15. Tissue alpha-fetoprotein and human chorionic gonadotrophin in non-seminomatous testicular tumours. A comparative study with serum levels.
Altug MU; Akdas A; Ruacan S; Ozen AH; Remzi D
Br J Urol; 1987 May; 59(5):458-62. PubMed ID: 2439163
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of five tumor markers (AFP, CEA, hCG, hPL and SP1) in monitoring therapy and follow-up of patients with testicular germ cell tumors.
Szymendera JJ; Zborzil J; Sikorowa L; Leńko J; Kamińska JA; Gadek A
Oncology; 1983; 40(1):1-10. PubMed ID: 6185897
[TBL] [Abstract][Full Text] [Related]
17. Tumor markers in patients with non-seminomatous germ cell tumors of the testis.
Willemse PH; Sleijfer DT; Schraffordt Koops H; De Bruijn HW; Oosterhuis JW; Brouwers TM; Ockhuizen T; Marrink J
Oncodev Biol Med; 1981; 2(1-2):117-28. PubMed ID: 6170952
[TBL] [Abstract][Full Text] [Related]
18. Quantification of alpha-fetoprotein and beta-HCG in testis tumor patients.
Dunzendorfer U; Jurincic C
Urol Int; 1987; 42(4):248-53. PubMed ID: 2445089
[TBL] [Abstract][Full Text] [Related]
19. Tumour markers in testicular cancer.
Light PA
J R Soc Med; 1985; 78 Suppl 6(Suppl 6):19-24. PubMed ID: 2582118
[No Abstract] [Full Text] [Related]
20. Does extragonadal presentation impart a worse prognosis to abdominal germ-cell tumours?
McAleer JJ; Nicholls J; Horwich A
Eur J Cancer; 1992; 28A(4-5):825-8. PubMed ID: 1381929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
